Skip to content
Saturday, May 31, 2025
Latest:
  • Renewing hope: A global push to improve neonatal outcomes
  • FROM THE LABS: Cell Painting identifies flavonoids that are toxic to bladder cancer cells
  • Menopause 101
  • New technique offers lasting relief for slipping rib syndrome
  • Ready for space travel? GENESTAR can track how space affects your health
Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Taylor Barnes
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Andy Phifer
      • Homa Shalchi
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu
From The Labs

From the labs to commercialization: Companies merge to implement Baylor College of Medicine-developed therapies for cancer

August 16, 2018 cancer therapy,  commercialization,  Marker Therapeutics,  Research,  T cells,  TapImmune,  tumor cells

Despite major advances in cancer therapy, conventional cancer treatments continue to be associated with devastating side effects for patients and are not always curative. In

Read More

From the Labs: Image of the Month

Blood vessels (magenta) intertwined with metastatic medulloblastoma tumor cells (green) nestled within the protective layers that surround the mouse spinal cord. From the Labs: a closer look at metastatic medulloblastoma

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951